secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-09-30T23:59:59+00:00
Accession:  0001493152-25-016168
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA completes SKNY acquisition, adds three pipeline programs; regains Nasdaq compliance
--------------------------------------------------------------------------------

- Acquired 100% of SKNY for restricted MIRA shares; SKNY contributed $5M in marketable securities to MIRA.
- Pipeline now includes Ketamir-2 (Phase 1 neuropathic pain), MIRA-55 (oral THC analog), and SKNY-1 (obesity/smoking cessation).
- Nasdaq had notified MIRA of stockholders' equity deficiency in April 2025; extension granted to Oct 6, 2025.
- After merger closing and ATM sales, MIRA believes it has regained compliance; Nasdaq will continue to monitor.
- No specific exchange ratio or deal value disclosed; valuations were independent third-party.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315225016168/0001493152-25-016168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315225016168/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-016168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer